Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer

Immunotherapy has significantly changed the treatment landscape for advanced non-small-cell lung cancer (NSCLC) with the introduction of drugs targeting programmed cell death protein-1 (PD-1) and programmed cell death ligand-1 (PD-L1). In particular, the addition of the anti-PD-1 antibody pembrolizu...

Descripción completa

Detalles Bibliográficos
Autores principales: Cavazzoni, Andrea, Digiacomo, Graziana, Alfieri, Roberta, La Monica, Silvia, Fumarola, Claudia, Galetti, Maricla, Bonelli, Mara, Cretella, Daniele, Barili, Valeria, Zecca, Alessandra, Giovannetti, Elisa, Fiorentino, Michelangelo, Tiseo, Marcello, Petronini, Pier Giorgio, Ardizzoni, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139811/
https://www.ncbi.nlm.nih.gov/pubmed/32178474
http://dx.doi.org/10.3390/cancers12030666

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139811/
https://www.ncbi.nlm.nih.gov/pubmed/32178474
http://dx.doi.org/10.3390/cancers12030666

Ejemplares similares